Zytiga is a prescription medication used primarily to treat prostate cancer, especially in patients with metastatic castration-resistant prostate cancer (mCRPC). It works by inhibiting the enzyme CYP17A1, which plays a key role in producing androgens (male hormones) that fuel prostate cancer growth. By reducing these hormones, Zytiga helps slow or stop the growth of cancer cells.
Indications:
- Metastatic Castration-Resistant Prostate Cancer (mCRPC): Used in combination with prednisone for men who have advanced prostate cancer and have not responded to standard hormone therapy.
- Castration-Sensitive Prostate Cancer: Zytiga is also used in combination with prednisone for newly diagnosed high-risk metastatic castration-sensitive prostate cancer.
How It Works: Zytiga targets the production of androgens in the adrenal glands, prostate, and even some other tissues, thereby reducing the amount of testosterone available to cancer cells. This action helps control tumor growth and may extend survival in patients with advanced prostate cancer.
Dosage and Administration: Zytiga is typically taken orally in tablet form, often in combination with prednisone to manage potential side effects related to low cortisol levels. It is important to follow the prescribed dosage and schedule to maximize effectiveness and minimize side effects.
Potential Side Effects: Common side effects include fatigue, joint pain, hot flashes, and gastrointestinal issues. Serious side effects can include high blood pressure, liver problems, and low potassium levels. Regular monitoring by healthcare providers is necessary.
